Core Insights - BioNexus Gene Lab Corp. has appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics, a company focused on precision oncology testing technologies, particularly minimal residual disease (MRD) liquid biopsy assays [1][2] - The appointment aims to enhance Fidelion's global commercial strategy and partnerships, facilitating the adoption of advanced oncology diagnostic technologies [2][3] Company Overview - BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology-focused company that advances innovation in biotechnology, precision diagnostics, and emerging technology platforms [9] - The company has a strategic investment in Fidelion and holds exclusive commercialization rights for the VitaGuard™ MRD technology across Southeast Asia [1][7] Leadership and Expertise - Dr. Meyyappan brings over 15 years of experience in precision oncology diagnostics and has held senior roles at various companies, including Menarini Silicon Biosystems and QIAGEN [4][5] - His expertise in commercial strategy and partnerships is expected to be crucial for the global adoption of next-generation diagnostic technologies [7] Market Trends - The minimal residual disease (MRD) testing segment is rapidly growing as healthcare systems increasingly adopt genomic technologies for early cancer recurrence detection and personalized treatment monitoring [3] - BioNexus and Fidelion are advancing commercialization initiatives for VitaGuard™ through laboratory partnerships and clinical collaborations [3]

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. (“Chemrex”). As part of this restructuring, Chemrex’s board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chie ...

BioNexus Gene Lab Corp ($BGLC), Fidelion, and Tongshu Gene, Patent Support Signing The CEO of BioNexus Gene Lab Corp. (Nasdaq: BGLC), Sam Tan with the CEO of Tongshu Gene, Dr. Yan Linghua, together with the BGLC and Fidelion Team during the signing of a Patent Support Agreement for the development of new, upgraded Patents & Global IP. KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics c ...

Core Insights - BioNexus Gene Lab Corp. has completed a strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology, enhancing its position in precision diagnostics and gene-based technologies [1][2] Strategic Acquisition - BGLC has acquired a 15% equity stake in Fidelion Diagnostics, which holds exclusive global commercial rights (excluding Greater China) to the VitaGuard™ Tumor-Naïve AI-oncology platform, providing BGLC shareholders with participation in Fidelion's international expansion [3] - The transaction allows BGLC to secure exclusive, perpetual rights to manufacture, market, and distribute the VitaGuard™ platform across all ASEAN markets, establishing it as the sole provider of this technology in a rapidly growing oncology region [4] Market Opportunity - The healthcare landscape in Southeast Asia is modernizing, with increasing demand for precision diagnostics and non-invasive cancer management tools, positioning BGLC to capture early-mover advantage [5] Transaction Structure - The deal was structured to maximize balance-sheet strength and minimize dilution, enabling BGLC to accelerate market entry and expand regional sales functions while preserving shareholder value [6] Value Creation Model - The transaction establishes a dual-asset value creation model, combining a high-margin commercial asset through exclusive ASEAN rights and an investment asset via the equity stake in Fidelion, ensuring benefits from both immediate commercial activity and long-term enterprise value creation [7][8] Financial Arrangement - The equity stake was acquired through a non-cash share exchange, aligning long-term interests between BGLC and Fidelion, while the commercial license fee is payable over 24 months, matching outflows to expected inflows [9] Management Commentary - The CEO of BGLC emphasized that this partnership elevates the company's strategic position, providing two distinct value levers: regional commercial expansion and exposure to Fidelion's international growth [10]

Core Insights - BioNexus Gene Lab Corp. (BGLC) has entered into a $500,000,000 Equity Purchase Agreement with ARC Group International Ltd. to enhance its capital position for strategic initiatives [1][4] - The agreement allows BGLC to issue and sell registered shares of its common stock to ARC over a 36-month period, with a one-time fee of 175,000 shares issued at a price of $4.32 [2] - The facility complements BGLC's existing $20 million At-The-Market program, providing financial flexibility while maintaining control over capital deployment [3] Advancing Precision Oncology - BGLC has executed a licensing agreement with Fidelion Diagnostics to commercialize the VitaGuard™ MRD assay, aimed at early cancer detection and monitoring [5] - The new facility will support clinical adoption and infrastructure development for MRD testing across Southeast Asia, including Malaysia, Singapore, Indonesia, and Thailand [5] Supporting CDMO Transformation - BGLC is expanding into contract development and manufacturing organization (CDMO) services, enhancing its capabilities in biologics production and high-performance diagnostics [6] - The facility will enable investments in quality systems, manufacturing capacity, and strategic partnerships aligned with global CDMO standards [6] Advancing Therapeutic Opportunities - BGLC is progressing a strategic partnership with BirchBioMed Inc. for a therapeutic candidate targeting fibrosis and skin regeneration [7] - The facility provides capital optionality to support clinical and regulatory preparations as the partnership moves forward [7] Company Overview - BioNexus Gene Lab Corp. is focused on precision medical diagnostics and expanding into contract development and manufacturing services across Southeast Asia [9] - The company is headquartered in Kuala Lumpur, Malaysia, and aims to enhance its capabilities in oncology diagnostics and biologics development [9]

Core Insights - BioNexus Gene Lab Corp. (BGLC) has entered into an Exclusive Intellectual Property License Agreement with Fidelion Diagnostics for the VitaGuard™ minimal residual disease (MRD) liquid biopsy platform in Southeast Asia [1][2][3] License Agreement Details - The license grants BGLC exclusive, irrevocable, royalty-free rights to use, develop, manufacture, market, distribute, and sell VitaGuard-based products and services in Southeast Asia [3] - BGLC will pay Fidelion a US$2 million license fee in 24 equal monthly installments and commit to at least US$500,000 in VitaGuard reagent and system purchases within the first 24 months [4] - The agreement is structured as a perpetual license, ensuring rights remain even if ownership of the underlying patents changes [5] Strategic Framework - The license agreement is part of a broader Share Subscription and Shareholders' Agreement, which positions BGLC as a strategic shareholder in Fidelion [2][6] - Management believes this agreement transforms a strategic framework into an operational business, enhancing BGLC's position in the MRD testing market [7] Market Potential - The global liquid biopsy market is projected to grow from approximately US$13.3 billion in 2025 to over US$22.88 billion by 2030, indicating a significant compound annual growth rate [9] - The MRD market is expected to increase from about US$1.4 billion in 2024 to roughly US$2.5 billion by 2029, representing a CAGR of over 12% [10] Regional Insights - Southeast Asia faces a rising cancer burden, with WHO estimating around 2.3–2.4 million new cancer cases and 1.5 million cancer deaths in 2022, with projections of an 80–85% increase in new cases by 2050 [13] - The region remains underpenetrated in advanced molecular diagnostics, with limited access to MRD testing outside a few top centers [14] - BGLC aims to establish itself as a first mover in the MRD market in Southeast Asia, focusing on building a recurring-revenue platform and a top-tier lab network [15]

Financial Performance - As of September 30, 2025, the Company recorded a net loss of $1,948,490 and negative cash flows from operating activities of $2,799,444, with an accumulated deficit of $5,391,110[38]. - For the nine months ended September 30, 2025, net revenue was $6,941,151, a slight decrease from $6,986,791 in the same period of 2024, representing a decline of approximately 0.65%[109]. - The net loss attributable to common shareholders for the nine months ended September 30, 2025, was $708,991, compared to a net loss of $1,345,370 for the same period in 2024, indicating an improvement of approximately 47%[135]. - The net loss attributable to common shareholders for the nine months ended September 30, 2025, was $1,948,490, compared to a net loss of $1,250,023 in 2024, representing an increase in loss of approximately 55.9%[140]. - For the three months ended September 30, 2025, the Company reported revenue of $2,543,823, a decrease of 3.3% compared to $2,630,376 for the same period in 2024[212]. - The gross profit for the three months ended September 30, 2025, was $377,685, representing an increase of 15.6% from $326,536 in the prior year[212]. - The Company experienced total other income of $107,760 for the three months ended September 30, 2025, significantly lower than $465,527 in the same period of 2024[212]. - Total operating expenses for the nine months ended September 30, 2025, were $1,187,954, compared to $2,129,685 in the same period of 2024, reflecting a decrease of approximately 44%[135]. Revenue and Segments - Revenue from the trading of industrial chemicals was $6,929,849 for the nine months ended September 30, 2025, compared to $6,975,567 in 2024, indicating a decrease of about 0.66%[109]. - The genomic screening services segment generated revenue of $4,768, while the trading of industrial chemicals segment contributed $2,539,055 for the three months ended September 30, 2025[135]. - Chemrex accounted for $2,539,055 (99.8%) of total revenue, a decrease of 3.4% from $2,627,813 (99.9%) in the previous year, primarily due to lower sales volume[218]. Assets and Liabilities - As of September 30, 2025, the Company's trade receivables amounted to $2,193,935, an increase from $1,894,448 as of December 31, 2024, representing a growth of approximately 15.9%[84]. - The total net trade receivables stood at $1,522,158 as of September 30, 2025, up from $1,376,571 as of December 31, 2024, indicating an increase of 10.6%[84]. - The Company has operating lease right-of-use assets of $186,082 as of September 30, 2025, down from $215,243 as of December 31, 2024, a decrease of 13.5%[95]. - Operating lease liabilities decreased to $183,746 as of September 30, 2025, from $210,557 as of December 31, 2024, representing a decline of 12.7%[96]. - As of September 30, 2025, total segment assets amounted to $7,621,228, down from $10,433,848 as of December 31, 2024, indicating a decrease of approximately 26.9%[142]. Cash and Liquidity - The Company maintains cash balances with multiple financial institutions in Malaysia, with deposits insured up to RM250,000 (approximately USD 55,000) per depositor[39]. - As of September 30, 2025, the Company had cash and cash equivalents of $1.36 million and total liquidity exceeding $5 million, providing a solid foundation for operational continuity and strategic investments[173]. - The Company is actively exploring additional capital-raising mechanisms, including at-the-market offerings and private placements, subject to Nasdaq and SEC compliance[174]. Credit and Allowances - The allowance for expected credit losses increased to $671,777 as of September 30, 2025, compared to $517,877 as of December 31, 2024, reflecting a rise of 29.6%[84]. - The Company applies a historical loss rate matrix for trade receivables, adjusted for forward-looking information and macroeconomic trends relevant to the industries in which customers operate[40]. - The allowance for credit losses is based on historical collection experience, aging of receivables, and current economic conditions, with specific allowances for customers with known financial difficulties[40]. Strategic Initiatives - The Company announced a strategic partnership with ML Tech to optimize Ethereum-based growth strategies, enhancing its position in digital asset management[146]. - A non-binding term sheet was entered into with Fidelion Diagnostics for exclusive commercialization rights of the VitaGuard™ MRD platform in Southeast Asia, with regulatory submissions planned for 2026[150]. - The Company plans to lead regulatory submissions for the VitaGuard™ MRD platform, capable of detecting cancer recurrence at variant allele frequencies as low as 0.02%, with a cost per test expected to be under $300[190]. - The Board of Directors authorized the strategic repositioning of Chemrex Corporation into a biotechnology-focused contract development and manufacturing organization, reallocating up to MYR 10 million for operational development[151]. Accounting and Compliance - The Company is evaluating the impact of ASU 2023-09 on its consolidated financial statements, which expands income tax disclosure requirements and is effective for annual reporting periods beginning after December 15, 2024[74]. - The Company does not expect any other recently issued accounting pronouncements to have a significant effect on its consolidated financial statements[75]. - The Company successfully achieved full Nasdaq compliance in April 2025, reinforcing market stability and investor confidence[187]. Stock and Shareholder Information - The company executed a one-for-ten reverse stock split on April 1, 2025, reducing the number of outstanding shares from 17,967,663 to 1,796,597[125]. - The Series Z Preferred Stock was created to facilitate a reverse stock split proposal, which was approved by shareholders on March 19, 2025[123]. - The Company filed a registration statement to register up to $100 million of securities and entered into an Equity Distribution Agreement for an aggregate offering price of up to $20 million[159].

Core Insights - BioNexus Gene Lab Corp. has entered into definitive agreements with Fidelion Diagnostics and Tongshu Biotechnology to commercialize the VitaGuard™ liquid-biopsy platform for minimal residual disease (MRD) testing [1][2][3] Strategic Highlights - The collaboration aims to support the development and commercialization of MRD testing in Southeast Asia, leveraging aligned ownership and operational support [2][3] - The goal is to replicate the cost reduction seen with the sub-$1,000 genome for MRD testing, making it more accessible [2][5] Transaction Details - BGLC will receive new shares from Fidelion equal to at least 15% of Fidelion's fully diluted share capital, while Fidelion will receive restricted BGLC shares equal to 19.9% of BGLC's pre-money outstanding shares [14] - The completion of the agreements is contingent upon an IP License Agreement granting BGLC exclusive commercialization rights across ASEAN [14] Clinical and Economic Impact - VitaGuard™ can detect circulating tumor DNA (ctDNA) down to 0.02% variant allele frequency at approximately 20,000× depth, recovering around 95% cfDNA [15] - The collaboration intends to broaden access to MRD testing in Southeast Asia, with an initial focus on Singapore and Malaysia [15] Next Steps - The parties expect to complete the agreements following the satisfaction of remaining conditions precedent within the specified period [6]

Core Viewpoint - BioNexus Gene Lab Corp. has filed a registration statement with the SEC to register up to $100 million of securities, aiming to enhance financial flexibility and support growth initiatives in precision diagnostics and gene-based technologies [1][3][4] Group 1: Financial Strategy - The company has entered into an Equity Distribution Agreement with Maxim Group LLC, allowing it to offer and sell up to $20 million of its common stock through an at-the-market (ATM) program [2] - The shelf registration and ATM facility are expected to provide structural capital readiness to support the execution of growth and operating initiatives [4] Group 2: Growth Initiatives - BioNexus is focusing on expanding its footprint in precision oncology, regenerative medicine, and contract biologics manufacturing through its subsidiaries MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. [3][6] - Recent partnerships with Fidelion Diagnostics Pte Ltd. and BirchBioMed Inc. are part of the company's strategy to drive growth [3] Group 3: Market Positioning - The company aims to transform into a next-generation biotechnology platform serving both Asian and U.S. markets [4] - BioNexus is building a platform that spans precision medicine, biologics manufacturing, and AI-integrated healthcare solutions [6]

Core Insights - BioNexus Gene Lab Corp (BGLC) has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. to advance the FS2 topical platform and enhance BGLC's biotech presence in Asia [1][2] Group 1: Partnership Details - BGLC will lead Birch's upcoming USD 10 million financing round through a strategic equity investment, aiming to accelerate the commercialization of Birch's FS2 topical platform in Southeast Asia [2] - The partnership combines BGLC's regional market access and infrastructure with Birch's innovative science in dermal regeneration and fibrosis control [2][5] Group 2: Proposed Terms - The Term Sheet is non-binding except for exclusivity and confidentiality provisions, which are binding for 60 days from execution [4] - BGLC will issue common shares representing 4.99 percent of its outstanding shares to Birch as part of the investment, while Birch will issue 1.5 million common shares to BGLC [9] Group 3: Strategic Support and Next Steps - BGLC will provide Birch with market intelligence, regulatory and clinical-trial strategy guidance, and assistance in securing licensees and commercialization partners for the FS2 topical cream in Malaysia and Singapore [9] - Both parties plan to negotiate a definitive agreement that includes customary representations, warranties, and closing conditions [9]